Spun out of Penn State University, Captis Diagnostics LLC is a molecular diagnostics company addressing early detection of cancers, personalized cancer medicine, and cancer therapeutic monitoring through a liquid biopsy, leveraging IP extracellular vesicle and circulating tumor cell enrichment technology. Captis will introduce its platform technology-based products and services for both research and clinical diagnosis based on its own proprietary technology, including: EV Isolation Kit, designed for use by academic and industry EVE researchers; EV Lung Cancer Targeted Therapy Kit, for patients with EGFR T790M mutation or EML4-ALK fusion, to ensure patients are being treated with the most effective targeted therapy for their specific DNA mutations (research & clinical diagnosis); EV Lung Cancer Diagnosis Kit, designed for both research and clinical diagnosis; EV Pancreatic Cancer Diagnosis Kit, for both research and clinical diagnosis.
